Evaluation of hypomethylating agents with or without venetoclax in patients with accelerated phase and blast phase myeloproliferative neoplasms: a HERO consortium study
Year: 2026
Type: article
Study design: Observational Study
Authors: Jenna Ciervo, Anthony J. Perissinotti, Adam J. DiPippo, Kayleigh Marx, Lydia L. Benitez, Caitlin Rausch, Kaitlyn Buhlinger, Benyam Muluneh, Hailey Hirata, Jeffrey Baron, Emma Uchida, Ashley Soule, Shawn P. Griffin, Benjamin J. Lee, Mimi Lo, Thu Doan, Janine Martino, Ila Saunders, Bernard L. Marini
Institutions: Memorial Sloan Kettering Cancer Center, University of Michigan, Michigan Medicine, The University of Texas MD Anderson Cancer Center, UNC Lineberger Comprehensive Cancer Center, Roswell Park Comprehensive Cancer Center, University of Kentucky HealthCare, University of California, Irvine, University of California, San Francisco, University of California San Diego
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7203828492